Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies
Top Cited Papers
- 1 September 2015
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 20 (9), 1061-1073
- https://doi.org/10.1016/j.drudis.2015.05.005
Abstract
No abstract availableKeywords
This publication has 82 references indexed in Scilit:
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences of the United States of America, 2012
- Reversible targeting of noncatalytic cysteines with chemically tuned electrophilesNature Chemical Biology, 2012
- Proteasome Inhibitors: An Expanding Army Attacking a Unique TargetCell Chemical Biology, 2012
- Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory PainThe Journal of pharmacology and experimental therapeutics, 2011
- Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH InhibitorACS Medicinal Chemistry Letters, 2010
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences of the United States of America, 2010
- Active site remodelling accompanies thioester bond formation in the SUMO E1Nature, 2010
- Beyond Picomolar Affinities: Quantitative Aspects of Noncovalent and Covalent Binding of Drugs to ProteinsJournal of Medicinal Chemistry, 2008
- Disparate proteome reactivity profiles of carbon electrophilesNature Chemical Biology, 2008
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences of the United States of America, 2008